ArticleMethods in molecular biology (Clifton, N.J.)2026
Ultra-Dilute Developability Analysis of Antibody Self-Association and Non-Specific Binding.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-stage screening of antibody developability properties is important for identifying monoclonal antibody (mAb) candidates with favorable biophysical properties in addition to potent biological activities. Nevertheless, this process is challenging given the large numbers of mAb candidates, as well as their low quantities, concentrations, and purities. Here, we report methods for assessing the developability of mAbs in terms of their levels of self-association and non-specific binding at ultra-dilute concentrations (~0.01-0.05 mg/ml). The self-association measurements using the AC-SINS and CS-SINS assays are performed by capturing mAbs on immunogold conjugates and evaluating their plasmon shifts in either formulation (CS-SINS) or physiological (AC-SINS) solution conditions. The non-specific binding measurements using the PSP assay are performed by capturing mAbs on Protein A-functionalized magnetic beads and evaluating their interactions with protein reagents in physiological solution conditions using flow cytometry. Using these methods in concert enables the identification of mAbs with reduced risk for development challenges associated with high self-association (e.g., high viscosity or low solubility) and high non-specific binding (e.g., fast antibody clearance).
Indexed as
Identifiers
42129096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.